Metagenomi Therapeutics (MGX) Assets Average (2024 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Assets Average of $209.0 million for Q1 2026, down 32.84% year-over-year from $311.2 million in Q1 2025, and down 10.87% quarter-over-quarter from $234.5 million in Q4 2025.
Metagenomi Therapeutics (MGX) Assets Average (2024 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Assets Average for 3 consecutive years, with $209.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 32.84% year-over-year to $209.0 million; the TTM figure through Mar 2026 stood at $209.0 million (down 32.84% YoY), while the FY2025 annual figure was $272.9 million, down 20.85% from the prior year.
- Assets Average retreated to $209.0 million in Q1 2026 per MGX's latest filing, from $234.5 million in the prior quarter.
- Across five years, Assets Average topped out at $400.7 million in Q2 2024 and bottomed at $209.0 million in Q1 2026.
- Historically, Assets Average has averaged $311.6 million across 3 years, with a median of $311.2 million in 2025.
- Annual changes were most pronounced in 2025 — Assets Average slipped 20.22% — and 2026, when it tumbled 32.84%.
- Metagenomi Therapeutics' Assets Average stood at $341.5 million in 2024, then plunged by 31.32% to $234.5 million in 2025, then retreated by 10.87% to $209.0 million in 2026.
- Business Quant data shows MGX's Assets Average at $209.0 million in Q1 2026, $234.5 million in Q4 2025, and $260.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Metagenomi Therapeutics | 45.38 Mn | 45.38 Mn | - | 185.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 185.33 Mn |
| Mar 31, 2026 | 209.03 Mn |
| Dec 31, 2025 | 234.52 Mn |
| Sep 30, 2025 | 260.11 Mn |
| Jun 30, 2025 | 285.08 Mn |
| Mar 31, 2025 | 311.23 Mn |
| Dec 31, 2024 | 341.47 Mn |
| Sep 30, 2024 | 372.13 Mn |
| Jun 30, 2024 | 400.65 Mn |
| Mar 31, 2024 | 390.12 Mn |